Reflexology Reduces Stress/Pain, Increases Energy During Breast Cancer RT

Commentary
Video

Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.

Significant improvements were seen in all evaluable metrics, including energy, anxiety, and pain, following integrative reflexology in patients undergoing radiation therapy for breast cancer, according to Heather Zinkin, MD.

CancerNetwork® spoke with Zinkin, chief of radiation medicine at Huntington Hospital of the Northwell Health Cancer Institute, about the data presented at the 2024 American Society of Radiation Oncology (ASTRO) Annual Meeting from a trial evaluating reflexology in patients being treated with radiotherapy for breast cancer. Specifically, she highlighted what the study revealed regarding the efficacy of this intervention on this patient group.

Zinkin began by expressing excitement on behalf of her research team that 21 months of data, which encompassed 560 patient encounters, were included for analysis. She followed by stating that significant improvements were made in all evaluable metrics, with particular emphasis on stress, pain, and energy.

She further explained that stress and pain were reduced by 40% and 24%, respectively, with energy levels increasing by 33%––all of which she said was clinically meaningful. She concluded by highlighting anecdotally reported improvements in radiotherapy experience among evaluable patients.

Investigators of the quality improvement study assessed 560 patient encounters from April 2022 through December 2023 to evaluate the impact of reflexology on patient-reported levels of stress, pain, and energy. Additional findings revealed a reported overall well-being improvement by 33.3% (P < .0001), with many patients reporting improvements to treatment-induced neuropathic pain. Investigators concluded that this integrative care approach may improve patient satisfaction, treatment-related adverse effects, and survival.

Transcript:

We were thrilled that we tabulated the first 21 months of data, which included 560 patient encounters, and we found significant improvements in all metrics, including energy, anxiety, and pain. Looking specifically at the numbers, stress was reduced by 40%, pain decreased by 24%, and energy increased by 33%. This was clinically meaningful, and patients anecdotally reported overall improvement in the whole experience of receiving radiation therapy.

Reference

Zinkin HD, Kostroff K, Dimisa D, et al. Reflexology as an integrative approach to improve stress, energy, and pain in women receiving radiotherapy for breast cancer. Int J Radiat Oncol. 2024;120(suppl 2):e423. doi:10.1016/j.ijrobp.2024.07.944

Recent Videos
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
Related Content